Protocol Development for Administration and AE Management of Bispecifics

Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.

EP: 1.Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

EP: 2.CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing

EP: 3.Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

Now Viewing

EP: 4.Protocol Development for Administration and AE Management of Bispecifics

EP: 5.Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management

EP: 6.Exploring the Management of Cytokine Release Syndrome (CRS)

Video content above is prompted by the following:

How did you develop your administration and adverse event monitoring and management protocols?

Recent Videos